Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova Pharmaceuticals. The deal – valued at up to $915 million – is due ...
Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary ...
Swedish Orphan Biovitrum AB (publ) (Sobi), an international specialty health-care company, aims to be recognized as a global leader in providing access to innovative treatments that transform the ...
Brenda Jordan, founder and chief executive, Sobi Analytics: ‘We show business owners what is going wrong in their businesses and tell them how to fix it.’ Picture: Bryan Meade Sobi Analytics, a ...
Apellis (APLS) Pharmaceuticals and Sobi announced that results from the Phase 3 VALIANT study were presented as an oral presentation during the High-Impact Clinical Trials session at the American ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback